About Molecular Detection
Molecular Detection is developing and commercializing a portfolio of sample-to-answer Detect-Ready molecular diagnostic tests for the rapid detection of infectious diseases. The Detect-Ready MRSA Panel allows for the rapid detection of methicillin-resistant Staphylococcus aureus (MRSA), a growing problem in hospitals and other health facilities around the globe. The screening panel includes a range of critical clinical targets for S. aureus and related pathogens. In addition to MRSA, the panel detects methicillin-sensitive S. aureus (MSSA), methicillin-resistant non-S. aureus and mixed samples, which are frequently encountered in clinical practice. In March and April 2012, Molecular Detection raised funding for a Series B recapitalization. The funds will be used primarily to further advance MDIA¢s Detect-Ready MRSA Panel and to develop MDIA¢s new molecular diagnostic panels for the detection of sepsis and gastrointestinal (GI) infections in hospitalized patients.
Molecular Detection Patents
Molecular Detection has filed 8 patents.
Sedatives, Hypnotics, Hormonal contraception, Barbiturates, Progestogens
Sedatives, Hypnotics, Hormonal contraception, Barbiturates, Progestogens
Latest Molecular Detection News
Oct 24, 2023
VedaBio – a biotechnology company focused on molecular detection – recently launched with over $40 million in funding backed by lead investor OMX Ventures and a select group of family offices, including Kleinmuntz Associates. VedaBio also unlocked the true power of CRISPR for molecular detection by developing the CRISPR Cascade, a revolutionary platform born from the intersection of engineering and biology. VedaBio’s CRISPR Cascade is a disruptive new molecular detection platform that works with unprecedented speed and accuracy. And the CRISPR Cascade platform eliminates the need for target amplification while maintaining PCR-level accuracy, all with an analytical turnaround time of less than 1 minute. Unlike PCR or other DNA/RNA amplification technologies where assay design complexity significantly increases with multiplexing, the CRISPR Cascade removes several fundamental constraints, enabling incredibly simple adn highly multiplexed assays without signal loss or cross-reactivity issues. Through performance that combines accurate and near-instant results, the CRISPR Cascade unlocks a universe of possibilities. VedaBio’s Executive Team: — Anurup Ganguli, PhD, Board Director, Co-Founder and Chief Executive Officer, brings expertise in the field of molecular detection, having developed multiple research platforms during his time at the University of Illinois at Urbana-Champaign in the lab of Professor Rashid Bashir, PhD, Co-Founder of VedaBio, Professor of Bioengineering, and currently Dean of The Grainger College of Engineering. — Frédéric Sweeney, PhD, Board Director, President and Chief Operating Officer, brings experience in startup and high-growth healthcare company environments with a focus on venture capital, corporate development and operations. Before joining VedaBio, Fred held numerous executive roles at MeMed Diagnostics, bioMérieux, Versant Ventures, Northern Biologics, and T2 Biosystems. —Christine Ginocchio, PhD, MT (ASCP), Chief Medical and Scientific Officer, is a renowned expert in molecular diagnostics and clinical microbiology. And she has been the principal investigator for more than 60 industry and pharmaceutical clinical trials that include 21 studies of in vitro diagnostic devices for US Food and Drug Administration (FDA) clearance. Her recent roles prior to joining VedaBio include Chief Scientific and Medical Officer at Quotient and Senior VP of Global Medical Affairs at bioMerieux/BioFire. Dr. Ginocchio was responsible for the oversight of global FilmArray Medical Affairs activities, the Investigator-Initiated Research Program, and medical training. She remains active in numerous professional societies and Editorial Boards and is a voting member of the President’s Advisory Council for Combating Antibiotic-Resistant Bacteria (PACCARB). The company also announced the appointment of leaders Will Harris as VP of Strategic Marketing, Ravi Vijayendran, PhD as SVP of Technical Operations and Quality, Don Masquelier, as VP Engineering, Phil Belgrader, PhD, as VP Systems Integration and Sally Brashear, VP Intellectual Property. Together, the VedaBio team boasts over 150 years of experience in every aspect of bringing innovative products to market successfully. KEY QUOTES: “With the CRISPR Cascade reaction, we have unlocked the true power of CRISPR with a platform that delivers near-instant molecular detection of highly multiplexed analytes with best-in-class accuracy, all without the need for target amplification. We believe it is poised to emerge as a future gold standard for molecular detection, empowering major advances across multiple applications including research and industrial tools, diagnostics and therapeutics.” — Anurup Ganguli, PhD, Co-Founder and Chief Executive Officer of VedaBio “It has been a true privilege to work with Anurup and the OMX Ventures team to bring a clear vision and rock-solid foundation of intellectual property, scientific excellence and a world-class team to life. At VedaBio, we are operating at the forefront of scientific innovation, creating a fundamental new model in the field of molecular detection. By combining the power of our platform with a strong focus on delivering products to solve real clinical and industrial needs, we are poised to transform clinical and operational workflows for the betterment of patients and consumers. Our goal is to provide access to true actionable information previously unattainable with prior molecular detection methods.” — Fred Sweeney, PhD, President and Chief Operating Officer, VedaBio Sponsors
Molecular Detection Frequently Asked Questions (FAQ)
When was Molecular Detection founded?
Molecular Detection was founded in 2007.
Where is Molecular Detection's headquarters?
Molecular Detection's headquarters is located at 400 E. Lancaster Avenue, Wayne.
What is Molecular Detection's latest funding round?
Molecular Detection's latest funding round is Recap - III.
How much did Molecular Detection raise?
Molecular Detection raised a total of $4.94M.
Who are the investors of Molecular Detection?
Investors of Molecular Detection include NuFund Venture Group, MentorTech Ventures, Mid-Atlantic Angel Group, Robin Hood Ventures, Elm Spring Holdings and 4 more.
Who are Molecular Detection's competitors?
Competitors of Molecular Detection include Natus Medical, Ikonisys, Binx Health, Veredus Laboratories, NanoMR and 7 more.
Compare Molecular Detection to Competitors
Binx Health is a healthcare company focused on point-of-care molecular diagnostics. The company offers diagnostic solutions that enable healthcare providers to deliver timely, high-quality care, including a testing platform for the diagnosis and treatment of chlamydia and gonorrhea infections. Binx Health primarily serves the healthcare industry. Binx Health was formerly known as Atlas Genetics. It was founded in 2005 and is based in Cambridge, Massachusetts.
Knoesis seeks to develop bio-analytical hardware and reagents enabling cost-effective clinical diagnostics. The vision of the company is to allow everyone affordable access to rapid and specific diagnostic healthcare knowledge. Knoesis' first application is an immunosensor for the detection of latent tuberculosis infection.
Micronics, Inc. is a developer of near patient in vitro diagnostic products for disease diagnosis, prognosis and treatment monitoring. The Company employs a core patent estate in microfluidics -- the ability to miniaturize complex tests onto credit card size disposable devices. Per the company, tests that today take hours to days in a central laboratory environment are processed on a Micronics disposable device in seconds to minutes.
Diamics, Inc. is a medical device and diagnostics company. The company is developing, manufacturing, and marketing cost effective cancer diagnostic systems that will increase long-term cancer survival rates through early detection.
ViralTest offers molecular-based diagnostics development for niche infectious diseases markets.
NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.